Elegance Optical International Holdings (0907) Fair Value & Analysis
Healthcare · HK · Market cap HK$53.2M
Fair value as of: Aug 13, 2026
From 2 valuation models · updated 2 days ago
Below-average quality, screening 39% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (HK$0.0848). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- The models converge in a tight band (HK$0.0848 to HK$0.0909), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0390 – HK$1.75 · fair‑value band HK$0.0848 – HK$0.0909 · the HK$0.0610 price screens below the HK$0.0848 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Elegance Optical International Holdings (0907) currently trades at HK$0.0610, while our model-based Fair Value estimate is HK$0.0848, implying the stock looks roughly 39.0% undervalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Elegance Optical International Holdings generated revenue of HK$62.0M at a net margin of 4.3%. It earns a return on equity of 52.6%. Net debt stands at HK$36.0M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0848 (bear case) to HK$0.0909 (bull case); at HK$0.0610, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 56% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 39%, 0907 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Notify me when 0907 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 27 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Elegance Optical International Holdings Limited, an investment holding company, manufactures and trades in optical frames and sunglasses in Europe, the United States, the People's Republic of China, and internationally.
Full company description
Elegance Optical International Holdings Limited, an investment holding company, manufactures and trades in optical frames and sunglasses in Europe, the United States, the People's Republic of China, and internationally. The company operates through Trading, Property Investment, Debts and Securities Investment, Film Investment and Distribution, and Energy Business segments. The Trading segment engages in the trading of optical frames and sunglasses. The Property Investment segment is involved in leasing of properties. The Debts and Securities Investment segment invests in financial instruments and quoted shares. The Film Investment and Distribution segment engages in the films copyrights, and movie investments and distribution business; and agency services. The Energy Business segment invests in energy sector related instrument, as well as trades in liquefied petroleum gas products. The company was formerly known as Elegance International Holdings Limited and changed its name to Elegance Optical International Holdings Limited in September 2013. Elegance Optical International Holdings Limited was incorporated in 1995 and is headquartered in Central, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Elegance Optical International Holdings reported revenue of HK$14.5M in FY2025 versus HK$53.9M in FY2021, a compound −28.0%/yr. Reported net income was −HK$20.2M in FY2025.
Watch 0907: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 202 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Elegance Optical International Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Elegance Optical International Holdings (0907) overvalued or undervalued?
What is the fair value of 0907?
What is the quality score of 0907?
What is the revenue of Elegance Optical International Holdings (0907)?
What is the net profit margin of 0907?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Elegance Optical International Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.